Who are omeprazole, 20mg twice daily's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nexium, Protonix, Protonix, Pantoprazole Sodium, Prevacid, Prilosec.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omeprazole-20mg-twice-daily.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

omeprazole, 20mg twice daily — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

omeprazole, 20mg twice daily (omeprazole, 20mg twice daily) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton Pump Inhibitor (PPI). Area: Metabolic.

marketed Proton Pump Inhibitor (PPI) H+/K+ ATPase enzyme Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

omeprazole, 20mg twice daily (omeprazole, 20mg twice daily) — Tel-Aviv Sourasky Medical Center. Omeprazole reduces stomach acid production by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
omeprazole, 20mg twice daily TARGET	omeprazole, 20mg twice daily	Tel-Aviv Sourasky Medical Center	marketed	Proton Pump Inhibitor (PPI)	H+/K+ ATPase enzyme
Nexium	esomeprazole	AstraZeneca	marketed	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Protonix	Pantoprazole Sodium	Baxter	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme system	2000-01-01
Pantoprazole Sodium	Pantoprazole Sodium	Pfizer	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme	2000-01-01
Prevacid	lansoprazole	Generic (originally Takeda)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase	1995-05-10
Prilosec	omeprazole	AstraZeneca (originally Astra AB)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19	1989-09-14

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-07 — Pantoprazole Sodium · 7544370 · US
2026-12-07 — Pantoprazole Sodium · 7544370*PED · US
2036-04-21 — Prevacid · 11077055 · Formulation · US
2036-04-21 — Prevacid · 11986554 · Formulation · US
2036-12-08 — Prilosec · 10835488 · Formulation · US
2036-12-08 — Prilosec · 10076494 · Formulation · US

Sponsor landscape (Proton Pump Inhibitor (PPI) class)

Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). omeprazole, 20mg twice daily — Competitive Intelligence Brief. https://druglandscape.com/ci/omeprazole-20mg-twice-daily. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab